Dr Joyce Cooper

Dr Joyce Cooper

Senior Lecturer

School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)

Career Summary

Biography

Dr Joyce Cooper is a registered pharmacist who has been working in the area of pharmacy for over 25 years. She initially worked as a hospital pharmacist both in the UK and Australia, as a clinical pharmacist and more latterly with responsibility as a Director of Pharmacy in tertiary hospitals. Dr Cooper also has an interest in community pharmacy practice and works an occasional locum in this area. Dr Cooper completed her PhD at the University of Newcastle, which focused on the factors that contribute to serotonin toxicity following drug overdose. During this time Dr Cooper worked with the Clinical Toxicology research group in the School of Medicine & Public Health, examining the pharmacokinetics of overdoses and the toxic effects of drugs.

In 2008, Dr Cooper took up an academic position in the School of Biomedical Sciences & Pharmacy at the University of Newcastle and has contributed to the teaching of both undergraduate and postgraduate pharmacy students. She is currently the Program Convenor for the Bachelor of Pharmacy (honours) Program. Dr Cooper also contributes to the teaching of postgraduate Nurse Practitioner students and to health professionals who are prescribers of medicines. In 2009, Dr Cooper completed the Post Graduate Certificate in the Practice of Tertiary Teaching which sparked her interest in researching methods used in teaching and learning and contributed to the development of a ‘virtual pharmacy’ model of a community pharmacy used for teaching in the Pharmacy Programs. https://virtualpharmacy.newcastle.edu.au/

Dr Cooper currently serves as the President of the Pharmacy Council of NSW, a regulatory role which is appointed by the Minster of Health. She was appointed as a member of the Pharmacy Council (NSW) in 2015.

Dr Cooper was also appointed as a Fellow of the Society of Hospital Pharmacists (FSHP) of Australia in 2019. She has been a member of this organisation since 2005, initially as a hospital pharmacist. She is a regular reviewer of submissions for the annual Medicines Management Conference for the Society.

 Research Expertise
Dr Cooper is a registered Pharmacist whose research focuses on medicines use and adverse effects of medicines. Current themes include: Antibiotic treatment in hospital outpatients in Hospital-in-the-Home services, and evaluation of pharmacy programs in both community and hospital settings.

Dr Cooper currently supervises 3 PhD students. She has successfully supervised 4 individual BPharmacy honours projects (since 2017).

Teaching Expertise
Dr Cooper’s teaching is now mainly focused around contemporary pharmacy practice in the Bachelor of Pharmacy (honours) Program. Her teaching includes teaching and co-ordinating the first- year course, Introduction to Pharmacy (PHAR1101) and the fourth year, Transition to Professional Practice courses (PHAR4102A & B). She also supervises several Pharmacy honours students undertaking individual (graded) or group honours projects in year 4 of the BPharmacy (hons) program. Her background and contemporary knowledge and practice in Pharmacy provides relevance and clinical context to her teaching.

Dr Cooper established, coordinated and taught Pharmacotherapeutics and Prescribing for Health Professionals (PHAR6701), taught extensively in the postgraduate Master of Pharmacy Program at the University of Newcastle (2008-2017), and was Program Convenor of the Master of Pharmacy Program (2015-2017).

Administration
2018-ongoing: Program Convenor, Bachelor of Pharmacy (hons) Program, School of Biomedical Sciences and Pharmacy

2015-2017: Master of Pharmacy Program Convenor, School of Biomedical Sciences and Pharmacy

2018-ongoing: President, Pharmacy Council of NSW

2015-ongoing: Pharmacist Member, Pharmacy Council of NSW

Peer review of Manuscripts: Dr Cooper is a regular reviewer for international journals including the International Journal of Pharmacy Practice (IJPP)


Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Science (Pharmacy), University of Sunderland - United Kingdom
  • Graduate Diploma in Clinical Pharmacy, University of Queensland
  • Graduate Certificate Practice of Tertiary Teaching, University of Newcastle

Keywords

  • Serotonin toxicity
  • clinical pharmacy
  • hospital pharmacy
  • pharmacogenomics
  • pharmacy practice
  • population PK-PD modelling
  • toxicology

Fields of Research

Code Description Percentage
080110 Simulation and Modelling 20
111503 Clinical Pharmacy and Pharmacy Practice 30
111506 Toxicology (incl. Clinical Toxicology) 50

Professional Experience

UON Appointment

Title Organisation / Department
Senior Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Membership

Dates Title Organisation / Department
1/1/2005 -  Membership - The Society of Hospital Pharmacists of Australia The Society of Hospital Pharmacists of Australia
Australia
1/1/1989 -  Membership - AHPRA AHPRA
Australia

Professional appointment

Dates Title Organisation / Department
1/7/2015 - 30/6/2021 Member of the Pharmacy Council of NSW

Appointed by the Minister for Health as President on 1 July 2018 - current

Pharmacy Council of New South Wales
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (15 outputs)

Year Citation Altmetrics Link
2020 Salem S, Cooper J, Schneider J, Croft H, Munro I, 'Student Acceptance of Using Augmented Reality Applications for Learning in Pharmacy: A Pilot Study.', Pharmacy (Basel, Switzerland), 8 1-10 (2020) [C1]
DOI 10.3390/pharmacy8030122
Co-authors Saad Salem, Hayley Croft, Jennifer Schneider
2019 Felkai C, Swinburne G, Cooper J, Kairuz T, 'Opioid pharmacotherapy: delivery in community pharmacy', Australian Pharmacist, 38 76-80 (2019)
Co-authors Therese Kairuz
2019 Hooper AD, Cooper JM, Schneider J, Kairuz T, 'Current and Potential Roles in Sports Pharmacy: A Systematic Review.', Pharmacy (Basel), 7 (2019) [C1]
DOI 10.3390/pharmacy7010029
Citations Web of Science - 3
Co-authors Jennifer Schneider, Therese Kairuz
2019 Bevan M, Ng YC, Cooper J, Robertson J, Walkom E, Chiu S, Newby DA, 'The role of evidence in consumer choice of non-prescription medicines', International Journal of Pharmacy Practice, 27 501-509 (2019) [C1]

© 2019 Royal Pharmaceutical Society Objectives: To identify factors influencing Australian consumer decision-making and attitudes towards non-prescription medicine (NPM) purchases... [more]

© 2019 Royal Pharmaceutical Society Objectives: To identify factors influencing Australian consumer decision-making and attitudes towards non-prescription medicine (NPM) purchases, pharmacy's role in providing these medications and views around sources of evidence for effectiveness of these products. Methods: Cross-sectional survey of a general population sample of 1731 adults using an Australian online consumer panel stratified by gender, age and location (State/Territory). Beliefs about NPM purchases and evidence of their efficacy were assessed using a 5-point Likert scale (strongly disagree-strongly agree). Non-parametric measures (Ridit analysis and Mann¿Whitney U-test) were used to explore associations between responses and previous experience with medicines. Key findings: The most important factors when purchasing NPMs were effectiveness and safety. However, personal experience was the most common method of determining effectiveness. Most respondents believed buying NPMs in pharmacies gave access to advice, but were less likely to agree that pharmacies were associated with safe and effective treatments. Around half the respondents agreed that it is wrong to sell treatments lacking scientific evidence; many also agreed that it is up to consumers to decide what they want even without scientific evidence. Individuals experiencing an ineffective NPM were less likely to trust scientific evidence of efficacy as the sole source of effectiveness information; regular prescription medicine users often agreed that scientific evidence is needed to support effectiveness. Conclusions: Consumers have conflicting views regarding the need for scientific evidence and the desire for patient autonomy in NPM purchases. This presents a challenge for pharmacists wishing to maintain professional obligations to provide evidence-based treatments to consumers.

DOI 10.1111/ijpp.12546
Citations Scopus - 1
Co-authors David Newby, Emily Walkom
2018 Tait L, Lee K, Rasiah R, Cooper JM, Ling T, Geelan B, Bindoff I, 'Simulation and Feedback in Health Education: A Mixed Methods Study Comparing Three Simulation Modalities.', Pharmacy (Basel, Switzerland), 6 (2018) [C1]
DOI 10.3390/pharmacy6020041
Citations Web of Science - 1
2017 Cooper JM, Brown JA, Cairns R, Isbister GK, 'Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects', Clinical Toxicology, 55 18-24 (2017) [C1]

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Context: Desvenlafaxine is used to treat major depression. Desvenlafaxine is also the active metabolite of venl... [more]

© 2016 Informa UK Limited, trading as Taylor & Francis Group. Context: Desvenlafaxine is used to treat major depression. Desvenlafaxine is also the active metabolite of venlafaxine. Venlafaxine overdose can cause serotonin toxicity, seizures and cardiovascular effects, but there is limited information on desvenlafaxine overdose. Objective: We aimed at investigating the clinical effects and complications from desvenlafaxine overdose. Materials and methods: This was a retrospective observational study of desvenlafaxine overdoses over a six-year period. Demographic details, dose and timing of the overdose, together with clinical effects, treatment and complications were extracted from a local hospital network database or the medical records of patients following hospital admission with a desvenlafaxine overdose. Results: There were 182 cases of desvenlafaxine overdose included in the study. From the 182 cases, 75 were desvenlafaxine (± alcohol) only ingestions and 107 included one or more co-ingested drugs. In single-agent desvenlafaxine ingestions, median age was 25 years (range: 13¿68 years) with a median ingested dose of 800 mg (range: 250¿3500 mg; interquartile range (IQR): 600¿1400 mg), and 54/75 (72%) were female. The Glasgow Coma Score (GCS) was 15 in 68/74 (92%) patients, 13¿14 in 5/74 (7%), and was seven in one patient following aspiration. Mild hypertension (systolic blood pressure [BP] > 140¿180 mmHg) occurred in 23/71 patients (32%), and tachycardia occurred in 29/74 (39%) patients. There were no abnormal QT intervals and no QRS >120 m s. Serotonin toxicity was diagnosed by the treating physician in 7/75 (9%) patients, but only one of these met the Hunter Serotonin Toxicity Criteria. None of the 75 patients who took desvenlafaxine only (± alcohol) had seizures, were admitted to intensive care or died. In comparison, the 107 patients taking desvenlafaxine in overdose with other medications developed more pronounced toxicity. Generalised seizures occurred in 5/107 (5%), but in three of these cases co-ingestants were possible proconvulsants. Fifteen patients had a GCS =9 and none had an abnormal QT or QRS. Severe effects appeared to be associated with coingestants. Conclusion: Desvenlafaxine overdose causes minor effects with mild hypertension and tachycardia. The risk of seizures or serotonin toxicity is low.

DOI 10.1080/15563650.2016.1223847
Citations Scopus - 4Web of Science - 4
Co-authors Geoffrey Isbister
2016 Isbister GK, Ang K, Gorman K, Cooper J, Mostafa A, Roberts MS, 'Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock', CLINICAL TOXICOLOGY, 54 881-885 (2016)
DOI 10.1080/15563650.2016.1209768
Citations Scopus - 3Web of Science - 4
Co-authors Geoffrey Isbister
2015 Michael AP, Mostafa A, Cooper JM, Grice J, Roberts MS, Isbister GK, 'Erratum: The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose (Clinical Toxicology (2015) (1-3))', Clinical Toxicology, 53 788 (2015) [O1]
DOI 10.3109/15563650.2015.1063280
Co-authors Geoffrey Isbister
2015 Cooper JM, Duffull SB, Saiao AS, Isbister GK, 'The pharmacokinetics of sertraline in overdose and the effect of activated charcoal', British Journal of Clinical Pharmacology, 79 307-315 (2015) [C1]

Aims To investigate the pharmacokinetics (PK) of sertraline in overdose and the effect of single dose activated charcoal (SDAC). Methods Patients presenting to a toxicology unit w... [more]

Aims To investigate the pharmacokinetics (PK) of sertraline in overdose and the effect of single dose activated charcoal (SDAC). Methods Patients presenting to a toxicology unit with sertraline overdoses had demographic and clinical information recorded, and serial serum collected for measurement of sertraline concentrations. Monolix® version 4.2 was used to develop a population PK model of sertraline overdose and the effect of SDAC. Uncertainty in dose time was accounted for by shifting dose time using lag time with between subject variability (BSV). BSV on relative fraction absorbed was used to model uncertainty in dose. Results There were 77 timed sertraline concentrations measured in 28 patients with sertraline overdoses with a median dose of 1550 mg (250-5000 mg). SDAC was given to seven patients between 1.5 and 4 h post-overdose. A one compartment model with lag time of 1 h and first order input and elimination adequately described the data. Including BSV on both lag time and relative fraction absorbed improved the model. The population PK parameter estimates for absorption rate constant, volume of distribution and clearance were 0.895 h-1, 5340 l and 130 l h-1, respectively. The calculated half-life of sertraline following overdose was 28 h (IQR 19.4-30.6h). When given up to 4 h post-overdose, SDAC significantly increased the clearance of sertraline by a factor of 1.9, decreased the area under the curve and decreased the maximum plasma concentration (Cmax). Conclusions Sertraline had linear kinetics in overdose with parameter values similar to those in therapeutic use. SDAC is effective in increasing clearance when given 1.5 to 4 h post-overdose.

DOI 10.1111/bcp.12500
Citations Scopus - 12Web of Science - 13
Co-authors Geoffrey Isbister
2015 Michael AP, Mostafa A, Cooper JM, Grice J, Roberts MS, Isbister GK, 'The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose', Clinical Toxicology, 53 633-635 (2015) [C1]

© 2015 Informa Healthcare USA, Inc. Objective. To describe the clinical effects, pharmacokinetics, and pharmacodynamics of plasma and acetylcholinesterase in an aldicarb overdose.... [more]

© 2015 Informa Healthcare USA, Inc. Objective. To describe the clinical effects, pharmacokinetics, and pharmacodynamics of plasma and acetylcholinesterase in an aldicarb overdose. Case Report. A 57-year-old female was found unconscious and incontinent of urine after ingesting aldicarb. She was bradycardic, hypotensive, hypersalivating, clammy, had small pupils, and generalized weakness. She was intubated, ventilated, and treated with large atropine doses (50 mg and 20 mg/h infusion) and adrenaline. She improved hemodynamically over 24 h, but remained comatose for another 24 h, before recovering without sequela. Aldicarb concentration at admission was 2.18 µg/ml and concentration-time data best fitted a two compartmental model with first order absorption and a time of ingestion 4.5 h preadmission. The half-life of distribution was 0.4 h and half-life of elimination, 13 h. Plasma cholinesterase concentration at admission was 0.3 kU/L (Reference range[RR]:4.3-10.6 kU/L) and red cell cholinesterase was 10 U/gHb (RR:38-66 U/gHb). The IC50 was 0.15 µg/ml and 0.26 µg/ml for plasma and red cell cholinesterase, respectively. Discussion. Aldicarb poisoning causes rapid onset severe toxicity with muscarinic and nicotinic excess, seizures, and decreased consciousness. Cholinesterases rapidly recover once aldicarb concentrations decrease and precede clinical recovery.

DOI 10.3109/15563650.2015.1054504
Citations Scopus - 3Web of Science - 2
Co-authors Geoffrey Isbister
2014 Cooper J, Garrett T, 'Providing medicines information and education to hospital in-patients: patients experiences and preferences', Journal of Pharmacy Practice and Research, 44 213-219 (2014) [C1]
Citations Scopus - 4
2014 Cooper JM, Newby DA, Whyte IM, Carter G, Jones AL, Isbister GK, 'Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT receptor', Pharmacogenomics J, (2014) [C1]
DOI 10.1038/tpj.2013.47
Citations Scopus - 5Web of Science - 6
Co-authors David Newby, Gregory Carter, Geoffrey Isbister
2014 Cooper J, Hookham G, Nesbitt KV, Rasiah RL, 'Developing a Virtual Tour of a Community Pharmacy for use in Education', IT in Industry, 2 33-37 (2014) [C1]
Co-authors Keith Nesbitt
2011 Gilligan C, Outram S, Rasiah RL, Cooper J, 'Exploring the attitudes of pharmacy students to clinical communications training', Focus on Health Professional Education, 13 25-36 (2011) [C1]
Co-authors Sue Outram, Conor Gilligan
2009 Cooper J, Jones AL, 'Neuroleptic malignant syndrome or a statin drug reaction? A case report', Clinical Neuropharmacology, 32 348-349 (2009) [C3]
DOI 10.1097/wnf.0b013e3181acc92d
Citations Scopus - 8Web of Science - 7
Show 12 more journal articles

Conference (15 outputs)

Year Citation Altmetrics Link
2018 Keegan M, Cooper J, Isbister GK, 'The clinical effects of duloxetine in overdose', Brisbane (2018)
Co-authors Geoffrey Isbister
2018 Keegan M, Cooper JM, Isbister GK, 'Duloxetine overdose', CLINICAL TOXICOLOGY (2018)
Co-authors Geoffrey Isbister
2018 Cooper JM, Duffull SB, Isbister GK, 'Serotonin toxicity: a regression analysis of frequency and outcomes', CLINICAL TOXICOLOGY (2018)
Co-authors Geoffrey Isbister
2017 Tait L, Lee K, Rasiah R, Cooper J, Ling T, Geelan T, Bindoff I, 'Exploring the use of a novel computer-based interactive pharmacy simulation program in university and professional pharmacy practice education', Exploring the use of a novel computer-based interactive pharmacy simulation program in university and professional pharmacy practice education, Brisbane (2017)
2015 Hookham G, Nesbitt K, Cooper J, Croft H, Rasiah R, 'Gamification for education: Designing a pharmacy education game', Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) (2015) [E1]

© Springer International Publishing Switzerland 2015. A key motivator for the use of serious games has been the notion that ¿gamification¿ provides users with an additional level ... [more]

© Springer International Publishing Switzerland 2015. A key motivator for the use of serious games has been the notion that ¿gamification¿ provides users with an additional level of engagement. This study examines a traditional model of usability in terms of engagement and efficacy, presenting the results obtained from a formative evaluation of a serious game prototype that has been developed to assist in pharmacy education.

DOI 10.1007/978-3-319-14803-8_12
Citations Scopus - 4Web of Science - 4
Co-authors Hayley Croft, Keith Nesbitt
2015 Coooper JM, Isbister GK, 'Desvenlafaxine overdose and the incidence of serotonin toxicity, seizures and cardiovascular effects', CLINICAL TOXICOLOGY (2015) [E3]
Co-authors Geoffrey Isbister
2014 Cooper J, Duffull SB, Saiao AS, Isbister GK, 'The effect of single-dose activated charcoal following sertraline overdose', The 40th SHPA National Conference: Book of Abstracts, Darwin (2014) [E3]
Co-authors Geoffrey Isbister
2014 Croft H, Rasiah R, Cooper J, Nesbitt K, 'Comparing Animation with Video For Teaching Communication Skills', Proceedings of the 2014 Conference on Interactive Entertainment, Newcastle, NSW (2014) [E1]
DOI 10.1145/2677758.2677777
Citations Scopus - 1
Co-authors Keith Nesbitt, Hayley Croft
2014 Hookham G, Cooper J, Rasiah R, Croft H, Nesbitt K, 'Efficacy and Usability in the Design of a Pharmacy Education Game', ENTERTAINMENT COMPUTING - ICEC 2014, Sydney, AUSTRALIA (2014) [E3]
Co-authors Keith Nesbitt, Hayley Croft
2014 Chalmers L, Nash R, Holmes S, Bereznicki L, Rasiah RL, Cooper JM, et al., 'Development of a benchmarking tool for pharmacy students using threshold learning outcomes', Hobart, Tasmania (2014)
2013 Cooper JM, 'Personalised Medicine: Predicting Serotonin Toxicity from Pharmacogenetic Studies', Final program and conference proceedings, Cairns, Qld. (2013) [E3]
2012 Cooper J, Garrett T, 'Providing medicines information - The experience of hospital patients', Final Program and Abstract Book. National Medicines Symposium 2012, Sydney, NSW (2012) [E3]
2010 Cooper J, Gilligan C, Outram S, Rasiah RL, 'Communication skills training in health programs at the University of Newcastle, Australia', International Conference on Communication in Healthcare 2010, Verona, Italy (2010) [E3]
Co-authors Conor Gilligan, Sue Outram
2009 Cooper J, Jones AL, 'Antipsychotic induced neuroleptic malignant syndrome: Or a simple drug interaction?', Across the Divide: Medicines Management 2009, The 35th SHPA National Conference: Abstracts, Posters, Perth, WA (2009) [E3]
2008 Cooper J, Pillay RD, Fung NK, Barry DA, Schwagger M, Inglis D, 'Getting to the bottom of it: Give a laxative with the opioid!', Medicines Management 2008: The 34th SHPA National Conference: Conference Handbook, Adelaide, SA (2008) [E3]
Show 12 more conferences

Creative Work (1 outputs)

Year Citation Altmetrics Link
2013 Croft H, Nesbitt KV, Rasiah R, Cooper J, Arrighi G, Joyce B, McGuire B, Communication Scenario: Over the Counter Dispensing of the Emergency Contraceptive Pill (Video and Animation - in 3 parts), Newcastle, NSW, Australia (2013) [J2]
Co-authors Keith Nesbitt, Gillian Arrighi

Other (1 outputs)

Year Citation Altmetrics Link
2014 Cooper JM, Duffull SB, Saiao AS, Isbister GK, 'The effect of activated charcoal on the pharmacokinetics of sertraline in overdose', ( pp.1): Conference Proceedings (2014) [O1]
Edit

Grants and Funding

Summary

Number of grants 3
Total funding $14,169

Click on a grant title below to expand the full details for that specific grant.


20122 grants / $13,399

Evidence-based community pharmacy practice: the use of evidence in selecting over-the-counter medicines$12,264

Funding body: Pharmacy Research Trust of NSW

Funding body Pharmacy Research Trust of NSW
Project Team Associate Professor David Newby, Doctor Joyce Cooper, Doctor Jane Robertson, Ms Yee Ching Ng, Mr Marc Bevan
Scheme Research Grant
Role Investigator
Funding Start 2012
Funding Finish 2016
GNo G1101183
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

National medicines Symposium, Sydney, 24 - 25 May 2012$1,135

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Doctor Joyce Cooper
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200539
Type Of Funding Internal
Category INTE
UON Y

20081 grants / $770

Medicines Management 2008 - SHPA (Society of hospital pharmacists of Australia) National Conference, Adelaide Convention Centre, 4/9/2008 - 6/9/2008$770

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Joyce Cooper
Scheme Travel Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0189369
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed0
Current3

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2020 PhD Review of the Treatment of Infection to Hospital Outpatients in Hospital-in-the-Home Programs; Including the Safety, Efficacy and Benefits of Treatment of Infection in HITH Programs and the Factors which may affect the Effectiveness of Treatment (with a view to Optimise Treatment, and Wherever Possible Adhere to AMS Pr PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2018 PhD The impact of clinical patient-centred medication interviews on chronic disease management in patients enrolled in medication assisted treatment for opioid dependence (MATOD) programs PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Sports Pharmacy: Investigating an Advanced Pharmacy Practice Model for Australian Pharmacists PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
Edit

Dr Joyce Cooper

Position

Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email joyce.cooper@newcastle.edu.au
Phone (02) 4921 2023
Fax (02) 4921 7903

Office

Room MS115
Building Medical Sciences
Location Callaghan
University Drive
Callaghan, NSW 2308
Australia
Edit